DarwinHealth

Last updated
DarwinHealth
Company typePrivate
Founded2015
FoundersAndrea Califano
Gideon Bosker
Headquarters
New York
,
United States
Website darwinhealth.com

DarwinHealth is an American biomedical company that uses algorithms and mathematical models in combination with wet lab experiments to develop cancer medicine. [1] [2] It is headquartered in New York, U.S. [3]

Contents

History

DarwinHealth was founded in 2015 by Andrea Califano and Gideon Bosker. [4] [5] Their collaboration began after a meeting in the British Virgin Islands in 2013. [6] The company's approach is to utilize algorithms developed in the Califano Lab at Columbia University to help physicians identify transcription factors in tumors and to predict potential drug targets and treatments. [6] [7]

In 2018, Daiichi Sankyo and DarwinHealth entered into a research collaboration centered on identifying novel cancer targets. [8]

In 2019, DarwinHealth and Celgene entered into a scientific collaboration to prioritize the oncology-relevant bioactivity of oncology compounds using its algorithmic framework with the goal of identifying their mechanism of action (MOA) against Master Regulator (MR) proteins. [9]

In 2021, Bristol Myers Squibb collaborated with DarwinHealth to explore compounds that might target master regulators within their compound library. [6] [10] In October 2021, DarwinHealth and Prelude Therapeutics collaborated to identify biomarkers for oncology drug trials. [11]

Research

In 2016, Andrea Califano of DarwinHealth, together with his colleague Mariano Alvarez, introduced the concept of "oncotecture" in a paper published in Nature Reviews Cancer. [12] They elucidated "master regulator" proteins that consistently impact tumor development across various patients. [12] By analyzing gene-expression profiles from 20,000 tumor samples, Califano identified approximately 300 potential master regulators across 36 tumor types. These proteins primarily influence transcription. [12]

In 2019, in a New England Journal of Medicine article titled, "Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma", analyzed patients from the STORM clinical trial for multiple myeloma. [13] In this trial, patients were treated with the XPO1 inhibitor selinexor. DarwinHealth scientists identified a Linear Discriminant Analysis (LDA) classifier using VIPER-assessed activity of only four proteins (IRF3, ARL2BP, ZBTB17, and ATRX). [13] The DarwinOncoMarker achieved a predictability measure (AUC = 0.862) in distinguishing responders from non-responders, a finding also confirmed in an independent cohort. [13]

In 2022, researchers from DarwinHealth published a paper in Current Protocols outlining the methodologies of the DarwinOncoDiscovery cancer drug discovery platform. [7] The protocol identifies tumor checkpoint MRs from patient samples and selects relevant in vitro and in vivo models to discern tissue-specific drug MOAs. [7] This method refines preclinical drug validations, enhancing the selection process for clinical trial participants. [7]

Products and services

Related Research Articles

<span class="mw-page-title-main">Multiple myeloma</span> Cancer of plasma cells

Multiple myeloma (MM), also known as plasma cell myeloma and simply myeloma, is a cancer of plasma cells, a type of white blood cell that normally produces antibodies. Often, no symptoms are noticed initially. As it progresses, bone pain, anemia, kidney dysfunction, and infections may occur. Complications may include hypercalcemia and amyloidosis.

<span class="mw-page-title-main">Lenalidomide</span> Pair of enantiomers

Lenalidomide, sold under the brand name Revlimid among others, is a medication used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (MDS). For multiple myeloma, it is a first line treatment, and is given with dexamethasone. It is taken by mouth.

<span class="mw-page-title-main">Bortezomib</span> Chemical compound

Bortezomib, sold under the brand name Velcade among others, is an anti-cancer medication used to treat multiple myeloma and mantle cell lymphoma. This includes multiple myeloma in those who have and have not previously received treatment. It is generally used together with other medications. It is given by injection.

<span class="mw-page-title-main">Personalized medicine</span> Medical model that tailors medical practices to the individual patient

Personalized medicine, also referred to as precision medicine, is a medical model that separates people into different groups—with medical decisions, practices, interventions and/or products being tailored to the individual patient based on their predicted response or risk of disease. The terms personalized medicine, precision medicine, stratified medicine and P4 medicine are used interchangeably to describe this concept, though some authors and organizations differentiate between these expressions based on particular nuances. P4 is short for "predictive, preventive, personalized and participatory".

<span class="mw-page-title-main">Targeted therapy</span> Type of therapy

Targeted therapy or molecularly targeted therapy is one of the major modalities of medical treatment (pharmacotherapy) for cancer, others being hormonal therapy and cytotoxic chemotherapy. As a form of molecular medicine, targeted therapy blocks the growth of cancer cells by interfering with specific targeted molecules needed for carcinogenesis and tumor growth, rather than by simply interfering with all rapidly dividing cells. Because most agents for targeted therapy are biopharmaceuticals, the term biologic therapy is sometimes synonymous with targeted therapy when used in the context of cancer therapy. However, the modalities can be combined; antibody-drug conjugates combine biologic and cytotoxic mechanisms into one targeted therapy.

<span class="mw-page-title-main">Plitidepsin</span> Chemical compound

Plitidepsin is a chemical compound extracted from the ascidian Aplidium albicans. It is currently undergoing clinical trial testing. It is a member of the class of compounds known as didemnins.

<span class="mw-page-title-main">Ipilimumab</span> Pharmaceutical drug

Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.

<span class="mw-page-title-main">ROS1</span> Protein-coding gene in the species Homo sapiens

Proto-oncogene tyrosine-protein kinase ROS is an enzyme that in humans is encoded by the ROS1 gene.

Minimal residual disease (MRD), also known as Molecular residual disease, is the name given to small numbers of cancer cells that remain in a person either during or after treatment when the patient is in remission. Sensitive molecular tests are either in development or available to test for MRD. These can measure minute levels of cancer cells in tissue samples, sometimes as low as one cancer cell in a million normal cells, either using DNA, RNA or proteins.

<span class="mw-page-title-main">Panobinostat</span> Chemical compound

Panobinostat, sold under the brand name Farydak, is a medication used for the treatment of multiple myeloma. It is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor.

<span class="mw-page-title-main">Genta (company)</span>

Genta Incorporated was a biopharmaceutical company started in La Jolla, California, which discovered and developed innovative drugs for the treatment of patients with cancer. Founded in 1989 by a highly skilled entrepreneur, the company focused on a novel technology known as antisense, which targets gene products that are associated with the onset and progression of serious diseases. At that time, only Ionis Pharmaceuticals, Inc. was conducting significant research with this technology. Antisense is a short span of oligonucleotides – modified DNA structures ranging from about 12-24 bases that selectively bind to specific RNA. The intent is to block expression of an aberrant protein that contributes to the disease of interest. Genta in-licensed three different antisense molecules that blocked Bcl-2, a fibroblast growth factor (FGF), and the gene c-myb, respectively.

<span class="mw-page-title-main">Compugen Ltd.</span> Israeli biotechnology company

CompugenLtd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors.

<span class="mw-page-title-main">Pembrolizumab</span> Pharmaceutical drug used in cancer treatment

Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is administered by slow intravenous injection.

The Icahn Genomics Institute is a biomedical and genomics research institute within the Icahn School of Medicine at Mount Sinai in New York City. Its aim is to establish a new generation of medicines that can better treat diseases afflicting the world, including cancer, heart disease and infectious pathogens. To do this, the institute’s doctors and scientists are developing and employing new types of treatments that utilize DNA and RNA based therapies, such as CRISPR, siRNA, RNA vaccines, and CAR T cells, and searching for novel drug targets through the use of functional genomics and data science. The institute is led by Brian Brown, a leading expert in gene therapy, genetic engineering, and molecular immunology.

<span class="mw-page-title-main">Filanesib</span> Chemical compound

Filanesib is a kinesin spindle protein (KIF11) inhibitor which has recently been proposed as a cancer treatment, specifically for multiple myeloma.

<span class="mw-page-title-main">Ixazomib</span> Chemical compound

Ixazomib is a drug for the treatment of multiple myeloma, a type of white blood cell cancer, in combination with other drugs. It is taken by mouth in the form of capsules.

<span class="mw-page-title-main">Melphalan flufenamide</span> Alkylating type cancer drug

Melphalan flufenamide, sold under the brand names Pepaxto and Pepaxti, is an anticancer medication used to treat multiple myeloma.

<span class="mw-page-title-main">Selinexor</span> Anti-cancer drug

Selinexor sold under the brand name Xpovio among others, is a selective inhibitor of nuclear export used as an anti-cancer medication. It works by blocking the action of exportin 1 and thus blocking the transport of several proteins involved in cancer-cell growth from the cell nucleus to the cytoplasm, which ultimately arrests the cell cycle and leads to apoptosis. It is the first drug with this mechanism of action.

Christine M. Lovly is an associate professor of medicine at Vanderbilt University. Her research involves the development of novel treatment strategies for ALK positive lung cancer.

<span class="mw-page-title-main">Andrea Apolo</span> American medical oncologist

Andrea B. Apolo is an American medical oncologist specialized in bladder cancer research. She is an investigator in the National Cancer Institute's genitourinary malignancies branch and head of the bladder cancer section.

References

  1. ↑ "DarwinHealth, Inc". Nature Index. October 31, 2023.
  2. ↑ "DarwinHealth Applies Systems Bio Workflow to Improve Clinical Trial Patient Matching | GenomeWeb".
  3. ↑ Califano, Andrea; Bosker, Gideon (23 September 2016). "Can Math Crack Cancer's Code?". Wall Street Journal.
  4. ↑ Echeverria, Gloria V.; Ge, Zhongqi; Seth, Sahil; Zhang, Xiaomei; Jeter-Jones, Sabrina; Zhou, Xinhui; Cai, Shirong; Tu, Yizheng; McCoy, Aaron; Peoples, Michael; Sun, Yuting; Qiu, Huan; Chang, Qing; Bristow, Christopher; Carugo, Alessandro; Shao, Jiansu; Ma, Xiaoyan; Harris, Angela; Mundi, Prabhjot; Lau, Rosanna; Ramamoorthy, Vandhana; Wu, Yun; Alvarez, Mariano J.; Califano, Andrea; Moulder, Stacy L.; Symmans, William F.; Marszalek, Joseph R.; Heffernan, Timothy P.; Chang, Jeffrey T.; Piwnica-Worms, Helen (2019). "Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state". Science Translational Medicine. 11 (488). doi:10.1126/scitranslmed.aav0936. PMC   6541393 . PMID   30996079.
  5. ↑ "About – DarwinHealth".
  6. 1 2 3 4 5 https://www.science.org/content/article/computer-algorithms-find-tumors-molecular-weak-spots
  7. 1 2 3 4 Laise, Pasquale; Bosker, Gideon; Califano, Andrea; Alvarez, Mariano J. (September 13, 2022). "A Patient‐to‐Model‐to‐Patient (PMP) Cancer Drug Discovery Protocol for Identifying and Validating Therapeutic Agents Targeting Tumor Regulatory Architecture". Current Protocols. 2 (9): e544. doi: 10.1002/cpz1.544 . PMID   36083100. S2CID   252160965 – via CrossRef.
  8. ↑ "Daiichi Sankyo And Darwinhealth Enter Exclusive Research Collaboration For Novel Cancer Target Initiative". Reuters. April 4, 2018.
  9. ↑ https://www.drugdiscoverynews.com/a-cancer-research-collaboration-13596
  10. ↑ "DarwinHealth, Bristol Myers Squibb sign research collaboration to identify novel cancer targets across a range of tumor subtypes". pharmabiz.com.
  11. ↑ "DarwinHealth, Prelude Therapeutics Partner to ID Biomarkers for Oncology Drug Trials". Precision Medicine Online.
  12. 1 2 3 "A new type of molecular medicine may be needed to halt cancers". The Economist.
  13. 1 2 3 Chari, Ajai; Vogl, Dan T.; Gavriatopoulou, Maria; Nooka, Ajay K.; Yee, Andrew J.; Huff, Carol A.; Moreau, Philippe; Dingli, David; Cole, Craig; Lonial, Sagar; Dimopoulos, Meletios; Stewart, A. Keith; Richter, Joshua; Vij, Ravi; Tuchman, Sascha; Raab, Marc S.; Weisel, Katja C.; Delforge, Michel; Cornell, Robert F.; Kaminetzky, David; Hoffman, James E.; Costa, Luciano J.; Parker, Terri L.; Levy, Moshe; Schreder, Martin; Meuleman, Nathalie; Frenzel, Laurent; Mohty, Mohamad; Choquet, Sylvain; Schiller, Gary; Comenzo, Raymond L.; Engelhardt, Monika; Illmer, Thomas; Vlummens, Philip; Doyen, Chantal; Facon, Thierry; Karlin, Lionel; Perrot, Aurore; Podar, Klaus; Kauffman, Michael G.; Shacham, Sharon; Li, Lingling; Tang, Shijie; Picklesimer, Carla; Saint-Martin, Jean-Richard; Crochiere, Marsha; Chang, Hua; Parekh, Samir; Landesman, Yosef; Shah, Jatin; Richardson, Paul G.; Jagannath, Sundar (August 22, 2019). "Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma". New England Journal of Medicine. 381 (8): 727–738. doi: 10.1056/NEJMoa1903455 . PMID   31433920. S2CID   201275272 – via CrossRef.
  14. 1 2 "Darwin OncoTarget™/OncoTreat™". Pathology. February 8, 2018.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.